overactive bladder
Conditions
Interventions
Mirabegron
Sponsors
Fujita Health University
Nagoya Ekisaikai Hospital Nagoya Memorial Hospital Minami Seikyo Hospital Chita city Hospital Aoyama Hospital Nakatugawa City Hospital Shizuoka Red Cross Hospital Hamamatsu Red Cross hospital Izumitani Fureai Clinic Mikawa Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Male and female patients with overactive bladder.(Q3:2over and OABSS total score:3over) 2 Patients attending physician has determined is reasonable to test participation. 3 The contents of the questionnaire can be understood without the aid of others. 4 Patients who consent in writing.
Exclusion criteria
Exclusion criteria: 1 Patients with a history of hypersensitivity to any component of this drug 2 Patients with severe heart disease /Heart rate increase, etc. have been reported, and Symptoms may be worse. 3 Women suspected of being pregnant and pregnant women 4 nursing woman. /Milk transfer has been observed animal experiments(in rats).In addition, this drug in lactation When administered to dams, reduced body weight gain and lower survival rates have been observed in the offspring. 5 Severe liver dysfunction patients (Child-Pugh score 10 or more) 6 Patients with propafenone hydrochloride or during flecainide acetate administration during. 7 Some of the urinary tract infection with active or chronic bacterial prostatitis. 8 Patients carried out pelvic radiation therapy 9 patients suspected prostate cancer by digital rectal examination or PSA. 10 Patienst with urethral stricture 11 Other things, the attending physician has determined to be inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| evaluation of OABSS at baseline and 12weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| bladder diary N-QOL AIS ESS | — |
Countries
Japan
Contacts
Public ContactHitomi Sasaki
Fujita Health University Urology
Outcome results
None listed